Literature DB >> 22695879

Ratio between positive lymph nodes and total excised axillary lymph nodes as an independent prognostic factor for overall survival in patients with nonmetastatic lymph node-positive breast cancer.

Hassan A Hatoum, Faek R Jamali, Nagi S El-Saghir, Khaled M Musallam, Muhieddine Seoud, Hani Dimassi, Jaber Abbas, Mohamad Khalife, Fouad I Boulos, Ayman N Tawil, Fadi B Geara, Ziad Salem, Achraf A Shamseddine, Karine Al-Feghali, Ali I Shamseddine.   

Abstract

BACKGROUND.: The status of the axillary lymph nodes in nonmetastatic lymph node-positive breast cancer (BC) patients remains the single most important determinant of overall survival (OS). Although the absolute number of nodes involved with cancer is important for prognosis, the role of the total number of excised nodes has received less emphasis. Thus, several studies have focused on the utility of the axillary lymph node ratio (ALNR) as an independent prognostic indicator of OS. However, most studies suffered from shortcomings, such as including patients who received neoadjuvant therapy or failing to consider the use of adjuvant therapy and tumor receptor status in their analysis. METHODS.: We conducted a single-center retrospective review of 669 patients with nonmetastatic lymph nodepositive BC. Data collected included patient demographics; breast cancer risk factors; tumor size, histopathological, receptor, and lymph node status; and treatment modalities used. Patients were subdivided into four groups according to ALNR value (<.25, .25-.49, .50-.74, .75-1.00). Study parameters were compared at the univariate and multivariate levels for their effect on OS. RESULTS.: On univariate analysis, both the absolute number of positive lymph nodes and the ALNR were significant predictors of OS. On multivariate analysis, only the ALNR remained an independent predictor of OS, with a 2.5-fold increased risk of dying at an ALNR of ≥.25. CONCLUSIONS.: Our study demonstrates that ALNR is a stronger factor in predicting OS than the absolute number of positive axillary lymph nodes.

Entities:  

Year:  2011        PMID: 22695879      PMCID: PMC3372966          DOI: 10.1007/s13193-011-0062-x

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  38 in total

1.  The eternally enigmatic axilla: further controversy about axillary lymph nodes in breast cancer.

Authors:  Kelly M McMasters
Journal:  Ann Surg Oncol       Date:  2003-12       Impact factor: 5.344

Review 2.  Implications of the sentinel lymph node procedure for local and systemic adjuvant treatment.

Authors:  Ann Smeets; Marie-Rose Christiaens
Journal:  Curr Opin Oncol       Date:  2005-11       Impact factor: 3.645

Review 3.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.

Authors:  M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang
Journal:  Lancet       Date:  2005-12-17       Impact factor: 79.321

4.  The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes.

Authors:  Pauline T Truong; Eric Berthelet; Junella Lee; Hosam A Kader; Ivo A Olivotto
Journal:  Cancer       Date:  2005-05-15       Impact factor: 6.860

Review 5.  Intraoperative lymphatic mapping and sentinel lymphadenectomy: community standard care or clinical investigation?

Authors:  D L Morton
Journal:  Cancer J Sci Am       Date:  1997 Nov-Dec

6.  Tumor volume, nodal status, and metastasis in breast cancer in women.

Authors:  E N Atkinson; B W Brown; E D Montague
Journal:  J Natl Cancer Inst       Date:  1986-02       Impact factor: 13.506

7.  Effect of the number of uninvolved nodes on survival in early breast cancer.

Authors:  Vincent Vinh-Hung; Gàbor Cserni; Tomasz Burzykowski; Jan van de Steene; Mia Voordeckers; Guy Storme
Journal:  Oncol Rep       Date:  2003 Mar-Apr       Impact factor: 3.906

8.  Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.

Authors:  Marianne Kyndi; Flemming B Sørensen; Helle Knudsen; Marie Overgaard; Hanne Melgaard Nielsen; Jens Overgaard
Journal:  J Clin Oncol       Date:  2008-02-19       Impact factor: 44.544

9.  Nodal stage classification for breast carcinoma: improving interobserver reproducibility through standardized histologic criteria and image-based training.

Authors:  Roderick R Turner; Donald L Weaver; Gabor Cserni; Susan C Lester; Karen Hirsch; David A Elashoff; Patrick L Fitzgibbons; Giuseppe Viale; Giovanni Mazzarol; Julio A Ibarra; Stuart J Schnitt; Armando E Giuliano
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544

10.  Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes correlates with traditional predictors of prognosis: an interim analysis of a prospective multi-institutional cohort study.

Authors:  William E Gillanders; Kaidi Mikhitarian; Renee Hebert; Patrick D Mauldin; Yuko Palesch; Christian Walters; Marshall M Urist; G Bruce Mann; Gerard Doherty; Virginia M Herrmann; Arnold D Hill; Oleg Eremin; Mohamed El-Sheemy; Richard K Orr; Alvaro A Valle; Michael A Henderson; Robert L Dewitty; Sonia L Sugg; Eric Frykberg; Karen Yeh; Richard M Bell; John S Metcalf; Bruce M Elliott; Thomas Brothers; Jay Robison; Michael Mitas; David J Cole
Journal:  Ann Surg       Date:  2004-06       Impact factor: 12.969

View more
  2 in total

1.  Prognostic Value of Lymph Node Ratio in Breast Cancer Patients with Adequate Pathologic Evidence After Neoadjuvant Chemotherapy.

Authors:  Xiang Ai; Xin Liao; Minghao Wang; Ying Hu; Junyan Li; Yi Zhang; Peng Tang; Jun Jiang
Journal:  Med Sci Monit       Date:  2020-04-29

2.  Predictive Value of Pretreatment Peripheral Neutrophil-to-Lymphocyte Ratio for Response to Neoadjuvant Chemotherapy and Breast Cancer Prognosis.

Authors:  Xiaomin Li; Qiuwen Tan; Hongjiang Li; Xiaoqin Yang
Journal:  Cancer Manag Res       Date:  2021-07-28       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.